Paradigm Sells Over 3.7 Million Shares of Erasca
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 43 minutes ago
0mins
Should l Buy ERAS?
Source: Fool
- Share Reduction Details: Paradigm Biocapital Advisors disclosed a sale of 3,766,393 shares of Erasca in Q1 2026, valued at approximately $44.52 million, indicating a cautious approach amid market volatility.
- Holding Proportion Change: Following this reduction, Erasca now represents 3.44% of Paradigm's assets under management, reflecting a decrease in its relative importance within the overall portfolio.
- Stock Performance: As of May 14, 2026, Erasca shares were priced at $10.37, marking a 716.5% increase over the past year, significantly outperforming the S&P 500 by 689.24 percentage points, showcasing strong market recognition of its developmental potential.
- Investment Risk Warning: Despite promising early clinical trial results, recent adverse events, including a patient death during trials, led to a 46% drop in stock price in a single day, highlighting the high-risk nature of biotech investments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ERAS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ERAS
Wall Street analysts forecast ERAS stock price to fall
8 Analyst Rating
6 Buy
1 Hold
1 Sell
Moderate Buy
Current: 10.230
Low
2.00
Averages
5.50
High
11.00
Current: 10.230
Low
2.00
Averages
5.50
High
11.00
About ERAS
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cormorant Asset Management Acquires Erasca Shares
- New Investment Position: Cormorant Asset Management disclosed a new position in Erasca on May 15, 2026, acquiring 5.8 million shares valued at approximately $68.55 million, indicating confidence in the company's clinical pipeline.
- Significant Holding: Erasca accounted for 4.71% of Cormorant's reportable assets in its 13F filing, highlighting the fund's recognition of Erasca's growth potential.
- Outstanding Stock Performance: As of May 14, 2026, Erasca's shares were priced at $10.37, reflecting a staggering 715% increase over the past year, significantly outperforming the S&P 500's 25% rise, which suggests positive market sentiment regarding its R&D progress.
- Strong Cash Position: Erasca ended the quarter with approximately $409 million in cash and marketable securities, expected to fund operations into the second half of 2028, indicating its potential in precision oncology despite currently having no approved products.
See More
Paradigm Sells Over 3.7 Million Shares of Erasca
- Share Reduction Details: Paradigm Biocapital Advisors disclosed a sale of 3,766,393 shares of Erasca in Q1 2026, valued at approximately $44.52 million, indicating a cautious approach amid market volatility.
- Holding Proportion Change: Following this reduction, Erasca now represents 3.44% of Paradigm's assets under management, reflecting a decrease in its relative importance within the overall portfolio.
- Stock Performance: As of May 14, 2026, Erasca shares were priced at $10.37, marking a 716.5% increase over the past year, significantly outperforming the S&P 500 by 689.24 percentage points, showcasing strong market recognition of its developmental potential.
- Investment Risk Warning: Despite promising early clinical trial results, recent adverse events, including a patient death during trials, led to a 46% drop in stock price in a single day, highlighting the high-risk nature of biotech investments.
See More
Biotech Fund Sells Erasca Stake After 700% Rally
- Share Reduction Details: Paradigm Biocapital Advisors disclosed the sale of 3,766,393 shares of Erasca in Q1 2026, valued at approximately $44.52 million, indicating a cautious approach to market volatility.
- Holding Proportion Change: Following this sale, Paradigm's stake in Erasca now represents 3.44% of its 13F AUM, reflecting a relative decline in importance within its portfolio and suggesting a reallocation towards other investments.
- Stock Performance: As of May 14, 2026, Erasca shares were priced at $10.37, marking a remarkable 716.5% increase over the past year, significantly outperforming the S&P 500 by 689.24 percentage points, demonstrating strong market confidence in its potential products.
- Investment Risk Advisory: Despite promising early clinical trial results, a recent incident involving a patient death led to a 46% drop in stock price in a single day, highlighting the high-risk nature of biotech investments and the need for investors to carefully assess timing.
See More
Acuta Capital Partners Initiates Position in Erasca
- New Investment Activity: According to an SEC filing dated May 15, 2026, Acuta Capital Partners initiated a new position in Erasca during Q1, acquiring 354,575 shares valued at approximately $4.19 million, indicating confidence in the company's potential.
- Stake Value Increase: By the end of the quarter, the value of Erasca's stake rose to $5.74 million, reflecting both the share acquisition and price fluctuations, despite a challenging market environment.
- Financial Condition: Erasca has a market capitalization of $3.15 billion, with a net loss of $277 million over the past 12 months, highlighting the company's significant investment in R&D and financial pressures.
- Clinical Trial Challenges: The ERAS-0015 candidate showed initial positive results in clinical trials, but a patient death raised investor concerns about its future, increasing the risks faced by the company.
See More
Erasca Under Investigation for Securities Fraud Claims
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of Erasca, Inc. investors regarding potential securities fraud or unlawful business practices by the company and its executives, which could significantly impact the company's reputation and stock price.
- Patent Infringement Allegations: On April 28, 2026, Erasca received a letter from Revolution Medicines alleging that its ERAS-0015 infringes on a patent and involves trade secret misappropriation, triggering a strong market reaction.
- Stock Price Plunge: Following the patent infringement news, Erasca's stock price fell by $9.25, or 48.3%, closing at $9.90 per share, indicating investor anxiety and a decline in confidence regarding the company's future.
- Potential Legal Consequences: The investigation may lead to a class action lawsuit against Erasca, and if misconduct by its executives is confirmed, it could have profound implications for the company's financial health and market performance.
See More
Erasca Under Investigation for Possible Securities Violations
- Significant Stock Drop: On April 28, 2026, Erasca disclosed receiving a letter from Revolution Medicines alleging that its ERAS-0015 infringes on a patent and involves trade secret misappropriation, causing its stock price to plummet from $19.15 to $9.90, a decline of approximately 48%, which severely impacts investor confidence.
- Legal Investigation Initiated: Kirby McInerney LLP has launched an investigation into possible violations of federal securities laws by Erasca and its senior management; although no lawsuit has been filed yet, this could lead to future legal liabilities and financial losses.
- Investor Rights Protection: The investigation aims to determine whether claims may be brought under federal securities laws, and investors with relevant information or seeking to learn more can contact the law firm to protect their rights, demonstrating a commitment to safeguarding investor interests.
- Industry Impact Assessment: The situation surrounding Erasca may trigger broader scrutiny of intellectual property protection and compliance within the biopharmaceutical industry, affecting operational strategies and investor confidence across other companies, potentially increasing legal risks in the sector.
See More
Cormorant Asset Management Acquires Erasca Shares
- New Investment Position: Cormorant Asset Management disclosed a new position in Erasca on May 15, 2026, acquiring 5.8 million shares valued at approximately $68.55 million, indicating confidence in the company's clinical pipeline.
- Significant Holding: Erasca accounted for 4.71% of Cormorant's reportable assets in its 13F filing, highlighting the fund's recognition of Erasca's growth potential.
- Outstanding Stock Performance: As of May 14, 2026, Erasca's shares were priced at $10.37, reflecting a staggering 715% increase over the past year, significantly outperforming the S&P 500's 25% rise, which suggests positive market sentiment regarding its R&D progress.
- Strong Cash Position: Erasca ended the quarter with approximately $409 million in cash and marketable securities, expected to fund operations into the second half of 2028, indicating its potential in precision oncology despite currently having no approved products.
See More
Paradigm Sells Over 3.7 Million Shares of Erasca
- Share Reduction Details: Paradigm Biocapital Advisors disclosed a sale of 3,766,393 shares of Erasca in Q1 2026, valued at approximately $44.52 million, indicating a cautious approach amid market volatility.
- Holding Proportion Change: Following this reduction, Erasca now represents 3.44% of Paradigm's assets under management, reflecting a decrease in its relative importance within the overall portfolio.
- Stock Performance: As of May 14, 2026, Erasca shares were priced at $10.37, marking a 716.5% increase over the past year, significantly outperforming the S&P 500 by 689.24 percentage points, showcasing strong market recognition of its developmental potential.
- Investment Risk Warning: Despite promising early clinical trial results, recent adverse events, including a patient death during trials, led to a 46% drop in stock price in a single day, highlighting the high-risk nature of biotech investments.
See More
Biotech Fund Sells Erasca Stake After 700% Rally
- Share Reduction Details: Paradigm Biocapital Advisors disclosed the sale of 3,766,393 shares of Erasca in Q1 2026, valued at approximately $44.52 million, indicating a cautious approach to market volatility.
- Holding Proportion Change: Following this sale, Paradigm's stake in Erasca now represents 3.44% of its 13F AUM, reflecting a relative decline in importance within its portfolio and suggesting a reallocation towards other investments.
- Stock Performance: As of May 14, 2026, Erasca shares were priced at $10.37, marking a remarkable 716.5% increase over the past year, significantly outperforming the S&P 500 by 689.24 percentage points, demonstrating strong market confidence in its potential products.
- Investment Risk Advisory: Despite promising early clinical trial results, a recent incident involving a patient death led to a 46% drop in stock price in a single day, highlighting the high-risk nature of biotech investments and the need for investors to carefully assess timing.
See More
Acuta Capital Partners Initiates Position in Erasca
- New Investment Activity: According to an SEC filing dated May 15, 2026, Acuta Capital Partners initiated a new position in Erasca during Q1, acquiring 354,575 shares valued at approximately $4.19 million, indicating confidence in the company's potential.
- Stake Value Increase: By the end of the quarter, the value of Erasca's stake rose to $5.74 million, reflecting both the share acquisition and price fluctuations, despite a challenging market environment.
- Financial Condition: Erasca has a market capitalization of $3.15 billion, with a net loss of $277 million over the past 12 months, highlighting the company's significant investment in R&D and financial pressures.
- Clinical Trial Challenges: The ERAS-0015 candidate showed initial positive results in clinical trials, but a patient death raised investor concerns about its future, increasing the risks faced by the company.
See More
Erasca Under Investigation for Securities Fraud Claims
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of Erasca, Inc. investors regarding potential securities fraud or unlawful business practices by the company and its executives, which could significantly impact the company's reputation and stock price.
- Patent Infringement Allegations: On April 28, 2026, Erasca received a letter from Revolution Medicines alleging that its ERAS-0015 infringes on a patent and involves trade secret misappropriation, triggering a strong market reaction.
- Stock Price Plunge: Following the patent infringement news, Erasca's stock price fell by $9.25, or 48.3%, closing at $9.90 per share, indicating investor anxiety and a decline in confidence regarding the company's future.
- Potential Legal Consequences: The investigation may lead to a class action lawsuit against Erasca, and if misconduct by its executives is confirmed, it could have profound implications for the company's financial health and market performance.
See More
Erasca Under Investigation for Possible Securities Violations
- Significant Stock Drop: On April 28, 2026, Erasca disclosed receiving a letter from Revolution Medicines alleging that its ERAS-0015 infringes on a patent and involves trade secret misappropriation, causing its stock price to plummet from $19.15 to $9.90, a decline of approximately 48%, which severely impacts investor confidence.
- Legal Investigation Initiated: Kirby McInerney LLP has launched an investigation into possible violations of federal securities laws by Erasca and its senior management; although no lawsuit has been filed yet, this could lead to future legal liabilities and financial losses.
- Investor Rights Protection: The investigation aims to determine whether claims may be brought under federal securities laws, and investors with relevant information or seeking to learn more can contact the law firm to protect their rights, demonstrating a commitment to safeguarding investor interests.
- Industry Impact Assessment: The situation surrounding Erasca may trigger broader scrutiny of intellectual property protection and compliance within the biopharmaceutical industry, affecting operational strategies and investor confidence across other companies, potentially increasing legal risks in the sector.
See More
